08:59 AM EDT, 08/11/2025 (MT Newswires) -- Veru ( VERU ) said Monday it selected a novel modified-release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management.

The selection was made following confirmation of pharmacokinetic endpoints in a clinical study, the company stated.

The novel modified-release oral formulation of enobosarm was developed in collaboration with Laxxon Medical using smart delivery systems, including Veru's ( VERU ) SPID technology to create advanced, unique oral delivery release profiles, as well as an additive manufacturing process, according to a statement.

The formulation is planned for use in Veru's ( VERU ) upcoming phase 3 clinical studies and commercialization for weight loss management, the statement said.

Veru ( VERU ) said it has been granted a meeting with the US Food and Drug Administration to discuss its phase 3 program.